Insulin degludec Reference

Plain English

What it is

Insulin degludec, sold under the brand name Tresiba, is a prescription long-acting (background, or basal) insulin. It is a lab-made version of the hormone insulin that helps the body control blood sugar.

What people use it for

Doctors prescribe it to help control blood sugar in adults and children who have type 1 or type 2 diabetes. It works slowly and steadily over a long period to provide a baseline level of insulin.

What the science shows

It is FDA-approved and backed by human studies. The official label describes it as a long-acting human insulin analog approved to improve blood sugar control in people 1 year of age and older who have diabetes.

The catch

This is a prescription diabetes medicine, not a fat-loss or performance tool. If the amount is wrong, it can cause severe low blood sugar, which the label warns can cause seizures and may be life-threatening or cause death. Low blood sugar is the most common side effect, so it should only be used under a doctor's care and individual guidance.

Reference summary

Insulin degludec is a label-verified ultra-long-acting basal insulin analog. pepSmart surfaces label-reference content only.

Regulatory and posture

Categories

Hormonal, Metabolic

Aliases

Tresiba, Ultra-long-acting basal insulin analog

Evidence posture

human - Prescription basal insulin. Severe hypoglycemia risk - incorrect dosing can be fatal. Not a research compound. Clinician-directed individualized titration is the only safe use.

Regulatory status

FDA-approved prescription medication (Tresiba). Indicated as basal insulin therapy in type 1 and type 2 diabetes. Prescription-only.

Content review status

label verified

Related tools

• Injection-site rotation overview - Public overview of the Pro site-rotation planner.